research affiliations

M.B.B.S. M.Sc. F.R.A.N.Z.C.P.

Publications    
REF 1.  Stampfer HG, Hood SD. Circadian rhythms: keeping pace with developments.  Med.J.Aust.  2009;191(9):479-80. [33%]
REF 2.     Robinson HM, Bell CJ, Hood SD, Nutt DJ, 2006, Dopamine and social anxiety disorder (Editorial), Revista Brasileira de Psiquiatria. 2006;28(4):263-4. [35%]
REF 3.     Argyropoulos S, Hood SD, Nutt DJ. Social Phobia: illness or illusion? (Editorial). Acta Psychiatrica Scandinavica  2001;103(4):241-423. [40%]        Peer-Reviewed Journals
REF 4.     Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers.  Prog. Neuropsychopharmacol.Biol.Psychiatry  2014;48:102-11.[20%]
REF 5.     McDonnell NJ, Kaye RM, Hood S, Shrivastava P, Khursandi DC. Mental health and welfare in Australian anaesthetists.  Anaesth.Intensive Care  2013;41(5):641-7.
REF 6.     Becerra R, Cruise K, Murray G, Bassett D, Harms C, Allan A, Hood SD. Emotion Regulation in Bipolar Disorder: Are Emotion Regulation Abilities Less Compromised in Euthymic Bipolar Disorder than Unipolar Depressive or Anxiety Disorders? Open Journal of Psychiatry. 2013;3: 1-7. doi: 10.4236/ojpsych.2013.34A001. [10%]
REF 7.     Hood S, Hudaib AR (2013) A Patient with a Pancreatic Endocrine Tumor develops Chronic Schizophrenia: Report of a Case. J Clin Case Rep 4:328. doi: 10.4172/2165-7920.1000328. [50%]
REF 8.     Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to important pathways associated with major depression: Diet, sleep and exercise.  J.Affect.Disord.  2013;148(1):12-27. [25%]
REF 9.     Hulse G.K, O’Neil A.G,  Morris N, Bennett K, Norman A, Hood SD. Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal:- a case series. Journal of Psychopharmacology. 2013;27(2):222-7. [10%]
REF 10.  Hood SD, Norman A, Hince DA, Melichar J, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil.  Br J Clin Pharmacol  2012; 77(2): 285-94 [33%]
REF 11.  Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.  J Psychopharmacol  2012;26(12):1512-24. [25%]
REF 12.  Lyons, Z. & Hood SD. Stigmatisation of Psychiatrists: Experiences of Psychiatrists and Psychiatric Registrars in Western Australia, Education Research and Perspectives, Vol.38, No.2., 2011: 20-34. [50%]
REF 13.  Bassiri, M., Lyons, Z. & Hood SD. Stigmatisation of Mental Illness and its Impact on Recruitment of Medical Students to a Career in Psychiatry. Education Research and Perspectives, Vol.38, No.2., 2011: 35-44. [33%]
REF 14.  Hood, S. & Chapman, E. A Tutorial Programme to Enhance Psychiatry Learning Processes within a PBL-Based Course, Education Research and Perspectives,  Vol.38, No.2., 2011: 69-86. [50%]
REF 15.  Kalk NJ, Melichar J, Holmes RB, Taylor LG, Daglish MR, Hood S, Edwards T, Lennox-Smith A, Lingford-Hughes AR, Nutt DJ. Central noradrenergic responsiveness to a clonidine challenge in Generalized Anxiety Disorder: a Single Photon Emission Computed Tomography study.  J.Psychopharmacol.  2012;26(4):452-460 [15%]
REF 16.  Garcia de Miguel B, Nutt DJ, Hood SD, Davies SJC. Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements – a systematic review. J Psychopharmacol, 2012; 26(4):431-442. [25%]
REF 17.  Bell C., Hood SD, Potokar J, Nash J, Adrover M, Frampton C, Hince D, Rich A, Argyropoulos S, Nutt DJ. Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder.  Psychopharmacology. 2011;213(2-3):593-602.[25%]
REF 18.  Starcevic V & Hood SD. Treatment-Refractory Generalized Anxiety Disorder. Psychiatr Ann. 2011 February;41(2):104-112. [50%]
REF 19.  Hood SD, Melichar JK, Taylor LG, Kalk N, Edwards TR, Hince DA, Lenox-Smith A, Lingford-Hughes AR, Nutt DJ. Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge.  J.Psychopharmacol.  2011;25(1):78-86. [50%]
REF 20.  Hood SD, Orr  KGD, Bennett L, Davies SJC. Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australasian Psychiatry; 2010 18(2): 174-176. [75%]
REF 21.  Hood SD, Hince DA, Davies SJC, Argyropoulos S, Robinson HM, Potokar J, Nutt DJ. Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology. 2010;208(2):223-32 [50%]
REF 22.  Christmas DM, Menon G, Hood SD. Recent Developments in Anxiety Disorders. Frontiers in CNS Drug Discovery. 2010, 1, 184-205. [33%]
REF 23.  Hood S, Potokar J, Davies S, Hince D, Morris K, Seddon K, Nutt D, Argyropoulos S. Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. Journal of Psychopharmacology. 2010; 24(5): 709-716 [50%]
REF 24.  Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, Srivastava S, Nutt DJ, Davies SJ. Antidepressant-induced jitteriness/anxiety syndrome: systematic review.  Br.J.Psychiatry  2009;194(6):483-90.
REF 25.  Hood SD. SSRIs as Antihypertensives in Patients with Autonomic Panic Disorder. Psychiatric Times. February 2009. 26(2):30-36. [100%]
REF 26.  Corchs F, Nutt DJ, Hood S, Bernik M. 5HT provides resilience to trauma-related exposure in SSRIs-recovered PTSD. Biological Psychiatry 2009.66(1): 17-24 [25%] REF
27.  Shufflebotham, J., Wetherall, M. A., Hince, D. A., Hood, S. D., Lightman, S. L., Nutt, D. J., Probert, C., & Potokar, J., Women with diarrhoea predominant irritable bowel syndrome show an increased pressor response to 35% carbon dioxide stress challenge. Stress  2009;12(1):30-6 [20%] REF
28.  Hood S, Davies S. Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al. Psychopharmacology. 2009; 203(4): 831-833.[75%]
REF 29.  Hood S, O’Neil G, Hulse G. The Role of Flumazenil in the Treatment of Benzodiazepine Dependence: Physiological & Psychological Profiles. Journal of Psychopharmacology. 2009;23(4):401-9 [75%]
REF 30.  Christmas D, Hood S, Nutt D. Potential Novel Anxiolytic Drugs. Current Pharmaceutical Design. 2008;14(33):3534-46. [33%]
REF 31.  Hood S, Shufflebotham J, Hendry J, Hince D, Rich A, Probert C, Potokar J. Irritable Bowel Syndrome (IBS) patients exhibit depressive and anxiety scores in the subsyndromal range. The Open Psychiatry Journal. 2008; 2: 12-22. [75%]
REF 32.  Davies SJC, Jackson P, Lewis G, Hood SD, Nutt DJ, Potokar J. Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?  Journal of Affective Disorders 2008; 111(2-3): 344-350. [25%]
REF 33.  Nash J, Sargent P, Rabiner E, Hood SD, Argyropoulos SV, Grasby P, Nutt DJ. A positron emission tomography study of serotonin 5-HT1A receptor availability in untreated and recovered patients with panic disorder. British Journal of Psychiatry 2008; 193(3): 229-234. [20%]
REF 34.  Harvey R, Smith M, Abraham N, Hood S, Tannenbaum D. The Hurricane Choir: Remote mental health monitoring of participants in a community-based intervention in the post-Katrina period.  Journal of Health Care for the Poor and Underserved 2007; 18(2):356-61. [33%]
REF 35.  Robinson H, Hood S. Social Anxiety Disorder - A Review of Pharmacological Treatments.  Current Psychiatry Reviews  2007; 3: 95-122 [65%]
REF 36.  Argyropoulos SV, Ploubidis GB, Wright T, Palm M, Hood S, Nash J, Taylor AC, Forshall S, Anderson IM, Nutt DJ, Potokar J.  Development and validation of the Generalized Anxiety Disorder Inventory (GADI).  Journal of Psychopharmacology 2007; 21 (2): 145-152. [10%]
REF 37.  Christmas D, Hood S. Recent Developments in Anxiety Disorders.  Recent Patents on CNS Drug Discovery 2006;1:289-98. [60%]
REF 38.  Shufflebotham J, Hood S, Hendry J, Hince DA, Morris K, Nutt D, Probert C, Potokar J. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome.  American Journal of Gastroenterology 2006;101(11):2582-7. [10%]
REF 39.  Nutt D, Argyropoulos S, Hood S, Potokar J. Generalized anxiety disorder: A comorbid disease.  European Neuropsychopharmacology  2006;16 Suppl 2:S109-S118. [15%]
REF 40.  Hood SD, Hince DA, Robinson H, Cirillo M, Christmas D, Kaye JM. Serotonin regulation of the human stress response. Psychoneuroendocrinology 2006;31(9):1087-97. [70%]
REF 41.  Davies SJC, Hood SD, Argyropoulos SV, Morris KV, Bell C, Witchel HJ, Jackson PR, Nutt DJ, Potokar J. Depleting Serotonin enhances both cardiovascular and psychological stress reactivity in humans.  Journal of Clinical Psychopharmacology. 2006;26(4):414-8. [33%]
REF 42.  Hood SD, Bell C, Nutt DJ. Acute tryptophan depletion. Part I: Rationale and Methodology.  Australian and New Zealand Journal of Psychiatry  2005;39:558-64. [65%]
REF 43.  Bell C, Hood SD, Nutt DJ. Acute tryptophan depletion. Part II: Clinical Effects and Implications.  Australian and New Zealand Journal of Psychiatry  2005;39:565-74. [45%]
REF 44.  Argyropoulos SV, Hood SD, Adrover M, Bell C, Rich A, Nash J, Rich N, Witchel H, Nutt DJ. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry 2004; 56(7): 503-9 [40%] REF
45.  McDonough S, Wynaden D, Finn M, McGowan S, Chapman R, Hood SD. Emergency Department Mental Health Triage Consultancy Service: An evaluation of the first year of the service.  Accident and Emergency Nursing  2004; 12: 31-38 [33%]
REF 46.  Hood SD, Argyropoulos SV, Nutt DJ. New directions in the treatment of anxiety disorders.  Expert Opinion on Therapeutic Patents 2003;13(4):401-24. [85%]
REF 47.  Wynaden D, Chapman R, McGowan S, McDonough S, Finn M, Hood SD. Emergency Department Mental Health Triage and Consultancy Service: A qualitative evaluation.  Accident and Emergency Nursing 2003;11(3):158-65 [15%]
REF 48.  Argyropoulos S, Bailey JE, Hood SD, Kendrick AH, Rich A, Laszlo G, Nash JR, Lightman SL and Nutt DJ.  Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology. 2002; 27: 715-729 [30%]
REF 49.  Bell C, Forshall S, Adrover M, Nash J, Hood SD, Argyropoulos S, Rich A, Nutt, DJ. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. Journal of Psychopharmacology 2002; 16 (1): 5-14 [20%]
REF 50.  Hood SD, Alderton D, Castle DJ. OCD: Treatment and Treatment Resistance. Australasian Psychiatry 2001;19:118-27 [85%]
REF 51.  Hood SD, Argyropoulos S, Nutt DJ. Arthritis and Serotonergic Antidepressants. Journal of Clinical Psychopharmacology 2000;21(4):458-61.[85%]
REF 52.  Hood, S.D., Argyropoulos, S., Nutt DJ. Agents in Development for Anxiety Disorders: Current Status and Future Potential. CNS Drugs 2000; 13(6): 421-431 [80%] Books
REF 53.  Castle D; Hood S; Starcevic V. (eds) Anxiety Disorders: Current Understandings, Novel Treatments. Australian Postgraduate Medicine; Melbourne 2012. [33% as editor]
REF 54.  Castle D, Hood S, Kyrios M. (eds) Anxiety Disorder: Current Controversies, Future Directions. Australian Postgraduate Medicine, Melbourne. 2007. [33% as editor]
REF 55.  Nutt DJ; Argyropoulos S; Hood SD. Clinician’s Manual on Anxiety Disorders and Comorbid Depression. London: Science Press; 2000 [Italian edition 2001]. [40%] Book Chapters
REF 56.  Hudaib AR, Hood SD. The biological treatment of anxiety: a review of progress. In  Castle D, Hood S, Starcevic V (eds)..Anxiety Disorders: Current Understandings, Novel Treatments. Melbourne: Australian Postgraduate Medicine;  2012 [50%]
REF 57.  Davies, S. J., Hood, S. D., Christmas, D., Nutt D.J. Psychiatric disorders and cardiovascular disease. Anxiety, depression and hypertension. In Psychological Factors and Cardiovascular Disorders: The Role of Psychiatric Pathology and Maladaptive Personality Features (ed L. Sher), New York: Nova Science Publishers. 2008 [30%]
REF 58.  Hood SD, Robinson H, Nutt DJ. In Castle D, Hood S, Kyrios M. (eds) Anxiety Disorder: Current Controversies, Future Directions. Australian Postgraduate Medicine, Melbourne. Chapter 20: New directions in biological treatments for anxiety disorders. 2007. [80%]
REF 59.  Hood SD, Robinson H, Nutt DJ. In Castle D, Hood S, Kyrios M. (eds) Anxiety Disorder: Current Controversies, Future Directions. Australian Postgraduate Medicine, Melbourne. Chapter 17: Pharmacological treatments for anxiety disorders: How do they work? 2007. [80%]
REF 60.  Hood SD, Nutt DJ.  In Crozier WR, Alden LE, editors. The essential handbook of social anxiety disorder for clinicians. Chichester: John Wiley & Sons, Ltd; Chapter 13: Psychopharmocological Treatments: An overview. 2005 [85%]
REF 61.  Bell C, Hood SD. In Joyce P, Mitchell P, editors. Mood Disorders. Chapter 25: Mood Disorders and Anxiety Disorders. Sydney: UNSW Press; 312-324. 2005. [50%]
REF 62.  Hood SD, Nutt DJ. In Crozier WR, Alden LE, editors. International Handbook of Social Anxiety: Research and Interventions relating to the Self and Shyness. Chichester: John Wiley & Sons, Ltd.; Chapter  21. Psychopharmacological Treatments – An Overview. September 2001 [85%]. Book Reviews
REF 63.  Essential Psychopharmacology: The Prescriber’s Guide. Journal of Psychopharmacology 2005 19: 681-682 [100%]
REF 64.  Anxiety Disorders: Pathophysiology and Pharmacological Treatment (Emilien, Durlach, Lepola, Dinan). International Journal of Psychiatry in Clinical Practice. 2003;7:72-3. [100%] Other Publications
REF 65.  Hood, S.D. Death of the academic psychiatrist?, Psychiatry in Australia 2012.
REF 66.  Hood, SD, Orr K, Nutt DJ. Antipsychotics. Psychiatry 2007; 6(7): 295-300. [80%]
REF 67.  Hood, SD. Nutt DJ. Psychopharmacology: Antipsychotics. Psychiatry 2004; 3(7): 27-30. [85%]
REF 68.  Hood, S.D. Adult Attention Deficit Disorder Treatment.  Pulse  2003;63(2):68 [90%]
REF 69.  Hood, S.D. Are there effective SAD treatments? Pulse 2000;60(14):112. [90%]
REF 70.  Hood, S.D. Low dose antidepressant prescription by GP’s. Pulse. 2000 60(13):120 [90%]
REF 71.  Hood, S.D. Why are antiepileptics useful in depression? Pulse. 2000; 60(8). [90%]
REF 72.  Hood, S.D. Which SSRI has least effect on sexual arousal? Pulse. 1999; 59(50). [90%]
REF 73.  Hood, S.D. and D.J. Nutt, Dysthymia: nosology and treatment. Perspectives in Depression 1999;7(3):3-7. [90%]
REF 74.  Hood, S.D. and D.J. Nutt, How I Treat – St John’s Wort. Practitioner. November 1999;243:779-786. [90%]
REF 75.  Hood, S.D., Argyropoulos S, Nutt D.J. SSRI’s and Social Phobia (Social Anxiety Disorder). Practical Issues in Mood and Anxiety Disorders. 1999; 9: 1-8. [65%]
REF 76.  Hood, S.D. and D.J. Nutt, Panic Disorder CNS. 2000; 2(4): 7-11. [75%]
REF 77.  Hood, S.D., Argyropoulos S, Nutt D.J. The efficacy of Paxil (paroxetine) for panic disorder. Current Practice of Medicine 1999;2(8):159-62. [80%]
REF 78.  Hood, S.D. and D.J. Nutt, Depression: Is improvement enough? Medical Dialogue, 1999 No. 508. [75%] Consumer Publications
REF 79.  Hood, S.D., A Living Hell: Psychological Treatments for Depression, 1999, BBC Education. [100%] Reports & Guidelines
REF 80.  Academic Perceptions of Teaching Environment (APOTE) survey. May 2011. The University of Western Australia. (steering committee).
REF 81.  Anxiety Guidelines. Western Australian Psychotropic Drugs Committee (WAPDC). August 2008, http://www.watag.org.au/wapdc/guidelines.cfm .
REF 82.  Antipsychotic Drug Guidelines. Western Australian Psychotropic Drugs Committee (WAPDC). version 3, August 2006, http://www.watag.org.au/wapdc/guidelines.cfm .
REF 83.  Sedation of Acutely Agitated Adult Patients Prior to Transportation. Western Australian Psychotropic Drugs Committee (WAPDC). January 2006, http://www.watag.org.au/wapdc/guidelines.cfm .
REF 84.  Antidepressants. Western Australian Psychotropic Drugs Committee (WAPDC). January 2005, http://www.watag.org.au/wapdc/guidelines.cfm .
REF 85.  Hood, S. D, McDonough, S, and Finn, M. Emergency Department Mental Health Triage And Consultancy Service "EMTACS". Pilot Phase: June – August 2001. Directorate of Mental Health, Fremantle Hospital and Health Service. September 2001.
REF 86.  Hood, S. D and Finn, M. Implementing The WA Strategic Quality Plan 1998 - 2003: Expression of Interest. Implementing Quality Initiatives in the State's Public Hospitals and Health Services. A submission by the Mental Health Directorate, Fremantle Hospital and Health Services.  2001. Conference Presentations (Posters & Orals)
REF 87.       Hood SD. Pharmacological Dissection of Anti-panic therapies. 11th World Congress of Biological Psychiatry. 24th June 2013. Kyoto, Japan (invited oral)
REF 88.       Hood SD. Efficacy of the antidepressant agomelatine in Generalised Anxiety Disorder: a randomised, double-blind, placebo controlled trial with active control. RANZCP 2013 Congress. 29th May 2013. Sydney, Australia (oral)
REF 89.       Hood SD. The Importance of Rhythm. Dialogues in Depression. 10th Nov 2012. Melbourne Australia (oral).
REF 90.       Hood SD. Are we submitting the right evidence? Dialogues in Depression. 23rd June 2012. Perth, Australia (oral & conference Chair).
REF 91.       Hood SD. Teaching yourself to debrief after critical incidents. Australian & New Zealand College of Anaesthetists Annual Scientific Meeting. 15th May 2012. Perth, Australia (invited oral).
REF 92.       Hood SD. The Death of the Academic Psychiatrist. Australian Psychiatry Expert Group Meeting. 20th- 22nd April 2012. Werribee, Victoria, Australia (invited oral).
REF 93.       Hood SD. Factors impacting the choice of antidepressant treatment: A case series. 16th April 2012. Ipoh, Malaysia (keynote oral).
REF 94.       Hood SD. Why should we treat depression in primary care? 15th April 2012. Petaling Jaya, Malaysia (keynote oral).
REF 95.       Hood SD. Choice of Antidepressant: An International Perspective. Pfizer Neuroscience Summit: Shifting the Paradigm in Mental Health. 14th April 2012. Malacca, Malaysia (keynote speaker).
REF 96.       Hood S & Hudaib A-R. Emerging medications for anxiety disorders. The Anxiety Spectrum Current Understandings, Novel Treatments 2011 Conference. 12th November 2011. Melbourne Australia (invited oral).
REF 97.       Hood, S. Novel approaches to the pharmacotherapy of generalised anxiety disorder. 2010 Sydney Anxiety Conference: Anxiety Disorders: Recent Developments and Outlook for the Future. 12th November 2010. Penrith, NSW, Australia (invited oral)
REF 98.       Hood, S. Anxiety Disorders & Cardiovascular Health. 2010 Sydney Anxiety Conference: Anxiety Disorders: Recent Developments and Outlook for the Future. 11th November 2010. Penrith, NSW, Australia (invited oral)
REF 99.       Hood, S. A Tale of 3 Cities, the Maastricht Masters & the Tryptophan Depletion story. XXII Summer Course on Anxiety Disorders, International Master of Affective Neuroscience. 8th July 2010. Villa Finaly, Florence, Italy. (ICANS Lecture)
REF 100.   Hood, S. Acute Tryptophan Depletion in 5 clinical anxiety disorders:PD, SAnD, PTSD, GAD & OCD. 27th June 2010. 1st Annual neurotalk. Singapore (oral & chair of session 5-16: Anxiety Pt II)
REF 101.   Hood, S. Specialist Symposium in Mental Health – Dimensions of Depression. (invited oral and expert panel). Melbourne, 22nd September 2008.
REF 102.   Tannenbaum, D., Barnes, C., Hood, S., Spiranovic, C., & Mitchell, P. (September 4-5, 2008). Developments in internet facilitated disease management systems: The application of Recovery Road in Mental Health. Paper presented at the 4th Annual National Disease Management Conference of the Australian Disease Management Association, InterContinental Sydney, Australia.
REF 103.   Kalk NJ, Melichar JK, Holmes RB, Hood SD, Taylor L, Daglish MRC, Parkin VJ, Rees MR, Lenox-Smith A, Lingford-Hughes A, Nutt DJ. Noradrenergic responsiveness in Generalised Anxiety Disorder: A SPECT study.  2008 Summer Conference of the British Association for Psychopharmacology. Harrogate, UK.
REF 104.   Hince DA, Hood SD, Robinson H, Rich A, Potokar J, Davies SJC, Argyropoulos SV, Nash J, Morris K, Potter J, Forward S, Morris L, Nutt DJ. Selective serotonin reuptake inhibitor-remitted patients with Generalised Anxiety Disorder do not show an increase in symptoms following acute tryptophan depletion. 2008 Summer Conference of the British Association for Psychopharmacology. Harrogate, UK. (poster & invited oral)
REF 105.   Hood SD, Melichar JK, Taylor SD, Daglish MRC, Holmes RB, Parkin VJ, Rees MR, Kalk N, Lenox-Smith A, Lingford-Hughes A, Nutt DJ. Noradrenergic function in generalised anxiety disorder (GAD): A single photon emission tomography (SPET) study.  26th CINP Congress. Munich, Germany 13-17 July 2008.
REF 106.   Tannenbaum, D., Barnes, C., Hood, S., Mitchell, P., & Spiranovic, C. Increasing the impact of disease management by using e-health systems. Singapore Disease Management Conference 2008, Suntec Convention Centre, Singapore. May 8-10, 2008.
REF 107.   Hood SD, Hince DA, Robinson H, Christmas D, Nutt DJ. Acute tryptophan depletion increases plasma prolactin in women but not men. 20th ECNP Conference. Vienna, Austria. 13-17 October 2007.
REF 108.   Christmas DM, Davies SJ, Sinclair LI, Hood SD, Potokar JP, Shrivastava S, Nutt DJ. A Systematic Review of Antidepressant Induced Jitteriness/Anxiety Syndrome. 20th ECNP Conference. Vienna, Austria. 13-17 October 2007.
REF 109.   Davies SJC, Christmas DM, Hood SD, Potokar JP, Shrivastava S, Nutt DJ. Antidepressant Induced Jitteriness/Anxiety Syndrome (Jas); A Systematic Review Of The Evidence. British Association for Psychopharmacology Summer Meeting. Harrogate, UK. July 22-25, 2006
REF 110.   Robinson HM, Hood S, Hince D, Cirillo M, Christmas D, Kaye J. Serotonin and 35% CO2 effects upon the human stress response, Feast of Psychiatry 2006, Fremantle, Western Australia
REF 111.   Hood SD, Argyropoulos SV, Davies SJ, Hince DA, Bell C, Nutt DJ, Potokar JP. The effect of acute tryptophan depletion on challenge induced anxiety in anxiety disorder patients is independent of a history of depression.  19th ECNP Conference. Paris, France. 15-20 Sep 2006.
REF 112.   Davies SJ, Hood SD, Argyropoulos SV, Hince DA, Morris K, Nutt DJ, Potokar JP. Serotonin reuptake inhibition and dopamine receptor antagonism together buffer the blood pressure response to stress in social anxiety disorder. 19th ECNP Conference. Paris, France. 15-20 Sep 2006.
REF 113.   Argyropoulos SV, Hood SD, Davies SJ, Hince DA, Morris K, Nutt DJ, Potokar JP. Dopaminergic challenges in social anxiety disorder.  19th ECNP Conference. Paris, France. 15-20 Sep 2006.
REF 114.   Harvey R, Smith M, Abraham N, Hood SD, Tannenbaum D. Using an e-disease management system to monitor population mental health after natural disasters: Experiences from an innovative trial. Health Outcomes 2006: Managing health and disease in today's society. Canberra, 9 - 10th August 2006
REF 115.   Srivastava S, Hood SD, Potokar JP, Bovell C, Nutt DJ. A 10 Year Review Of Moclobemide Prescribing In A Specialist Clinic.  British Association for Psychopharmacology Summer Meeting. Oxford, UK. July 23-26, 2006
REF 116.   Robinson H, Hood SD, Hince D, Cirillo M, Christmas D, Kaye J. Serotonin and 35% CO2 effects upon the human stress response. British Association for Psychopharmacology Summer Meeting. Oxford, UK. July 23-26, 2006
REF 117.   Seddon KM, Hood SD, Morris K, Davies SJC, Potokar J, Nutt DJ, Argyropoulos SV. The effect of the dopamine agonist pramipexole and antagonist sulpiride on anxiety induced in social anxiety disorder patients treated with a SSRI. British Association for Psychopharmacology Summer Meeting. Oxford, UK. July 23-26, 2006
REF 118.   Davies SJC, Hood SD, Argyropoulos SV, Hince D, Morris K, Morris K, Nutt DJ, Potokar J. Serotonin reuptake inhibition and dopamine receptor antagonism together buffer the blood pressure response to stress in social anxiety disorder. British Association for Psychopharmacology Summer Meeting. Oxford, UK. July 23-26, 2006
REF 119.   Hood SD, Robinson H, Hince D, Cirillo M, Christmas D, Kaye J. Serotonin regulation of the human stress response. 41st Congress Royal Australian & New Zealand College of Psychiatrists. Perth, Australia, 28 May – 1 Jun 2006.
REF 120.   Davies SJC, Jackson PR, Lewis G, Hood SD, Nutt DJ, Potokar J. Panic Attacks More Likely To Include Autonomic Symptoms In Patients With Hypertension Than In Normotensives – A Comparison Of Symptoms, And Factor Analysis. ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe. Nice, France. 9-12 Mar 2006
REF 121.   Hood SD, Davies SJC, Argyropoulos SV, Bell C, Jackson PR, Nutt DJ, Potokar J. Hypertension And Anxiety – Serotonin Depletion Associated With Consistent Excess Pressor Response To Stress Challenge In Patients With Treated Anxiety Disorders.  International Anxiety Disorders Conference. Stellenbosch, South Africa, 24-26 Feb 2006.
REF 122.   Hood SD, Robinson H, Hince D, Cirillo M, Christmas D, Kaye J. Serotonin regulation of the human stress response. International Anxiety Disorders Conference. Stellenbosch, South Africa, 24-26 Feb 2006.
REF 123.   Fellows L, Western Australian Psychotropic Drugs Committee (WAPDC). Guidelines for sedation of acutely agitated adult patients prior to transportation. 13th Rural & Remote Mental Health Conference. Albany, Australia, 16-17 Feb, 2006.
REF 124.   Davies SJC, Hood SD, Argyropoulos SV, Bell CJ, Jackson P, Nutt DJ, Potokar J.  Hypertension And Anxiety – Serotonin Depletion Associated With Consistent Excess Pressor Response To Stress Challenge In Patients With Treated Anxiety Disorders. 44th Annual Meeting, American College of Neuropsychopharmacology [ACNP] Hawaii, 11-15 Dec 2005. (by invitation)
REF 125.   Davies SJC, Hood SD, Argyropoulos SV, Bell CJ, Jackson P, Nutt DJ, Potokar J.  Hypertension And Anxiety – Serotonin Depletion Associated With Consistent Excess Pressor Response To Stress Challenge In Patients With Treated Anxiety Disorders. 18th ECNP Congress. Amsterdam, The Netherlands, 22-26 Oct 2005.
REF 126.   Davies SJC, Hood SD, Argyropoulos SV, Bell C, Jackson PR, Nutt DJ, Potokar J. Hypertensive And Anxiety – Serotonin Depletion Associated With Consistent Excess Pressor Response To Stress Challenge In Patients With Treated Anxiety Disorders. Fifteenth European Meeting on Hypertension. Milan, Italy. June 17-21 2005.
REF 127.   Potokar J, Shufflebotham J, Hood SD, Hendry J, Rich AS, Probert C, Nutt, DJ. Acute tryptophan depletion has differential effects on mood and GI symptoms in IBS. Bristol Neurosciences Meeting. Bristol, UK. April 13, 2005.
REF 128.   Davies SJC, Hood SD,  Argyropoulos SV, Morris KA, Bell CJ, Witchel HJ, Jackson PR, Nutt DJ, Potokar J. Depleting brain serotonin markedly enhances both cardiovascular and psychological stress reactivity in humans. Bristol Neurosciences Meeting. Bristol, UK. April 13, 2005.
REF 129.   Hood SD, Argyropoulos SV, Davies SJC, Wilson S, Nutt DJ. Effect of a single dose of a dopaminergic antagonist (sulpiride) and a dopaminegic agonist (pramipexole) in patients with social anxiety disorder, before and after treatment with a serotonergic antidepressant. Australasian Society for Psychiatric Research Annual Scientific Meeting. Fremantle, Australia. December 2-3, 2004.
REF 130.   Nash J, Sargent P, Rabiner E, Hood SD, Argyropoulos SV, Grasby P, Nutt DJ. Altered 5HT1A binding in panic disorder demonstrated by positron emission tomography.  17th ECNP Congress. Stockholm Sweden, October 9-13 2004.
REF 131.   Hood SD, Argyropoulos SV, Potokar J, Bell CJ, Shufflebotham J, Rich AS, Nutt, DJ. A meta-analysis of acute tryptophan depletion studies in anxiety disorders using individual patients’ data. The University of Western Australia School of Psychiatry and Clinical Neurosciences Early Career Researchers Symposium. Perth, Australia. August 17, 2004.
REF 132.   Hood SD, Argyropoulos SV, Potokar J, Bell CJ, Shufflebotham J, Rich AS, Nutt, DJ. Early results from a Tryptophan Depletion (TD) study in Panic Disorder (PD) patients treated with Cognitive Behavioural Therapy (CBT). The University of Western Australia School of Medicine and Pharmacology: Pharmacology Unit Annual Research Day. Perth, Australia. August 17, 2004.
REF 133.   Hood SD, Argyropoulos SV, Potokar J, Bell CJ, Shufflebotham J, Rich AS, Nutt, DJ. A meta-analysis of acute tryptophan depletion studies in anxiety disorders using individual patients’ data. 2004 Summer Conference of the British Association for Psychopharmacology. Harrogate, UK.
REF 134.   Hood SD, Shufflebotham J, Probert C, Potokar J. Psychological symptoms in irritable bowel syndrome (IBS). 2004 Summer Conference of the British Association for Psychopharmacology. Harrogate, UK.
REF 135.   Hood SD, Nash JR, Bell CJ, Hurst J, Adrover MDM, Pyle AC, Rich AS, Slattery HL, Potokar JP, Nutt DJ. Early results from a tryptophan depletion study in panic disorder patients treated with cognitive behavioural therapy. 2004 Summer Conference of the British Association for Psychopharmacology. Harrogate, UK.
REF 136.   Hood SD, Argyropoulos SV, Potokar J, Bell CJ, Shufflebotham J, Rich AS, Nutt, DJ. A meta-analysis of acute tryptophan depletion studies in anxiety disorders using individual patients’ data. XXIVth CINP Congress. Paris, France. June 20-24, 2004.
REF 137.   Bell CJ, Argyropoulos SV, Hood SD, Forshall S, Nutt DJ. The effects of acute tryptophan depletion in patients with panic disorder and social anxiety disorder who have responded to treatment with SSRIs. International Congress of Biological Psychiatry. Sydney, Australia. February 9-13 2004.
REF 138.   Nutt DJ, Nash J, Bell C, Adrover M, Sargent P, Rabiner E, Hood SD, Argyropoulos SV, Grasby P. Antidepressant mechanisms in anxiety disorders.   16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, September 20-24, 2003.
REF 139.   Nash J, Sargent P, Rabiner E, Hood SD, Argyropoulos SV, Grasby P, Nutt DJ. Altered 5HT1A binding in panic disorder demonstrated by PET scanning.  British Association for Psychopharmacology Summer Meeting. Cambridge, UK. July 20-23, 2003
REF 140.   Shufflebotham J, Probert C, Potokar J, Hood SD.  Tryptophan Depletion Study in Irritable Bowel Syndrome (IBS). British Association for Psychopharmacology Summer Meeting. Cambridge, UK. July 20-23, 2003
REF 141.   Shufflebotham J, Probert C, Potokar J, Hood SD.  Tryptophan Depletion Study in Irritable Bowel Syndrome (IBS). Annual South West Gastroenterology Society Meeting. Devon, UK. June 20-26, 2003
REF 142.   Shufflebotham J, Probert C, Potokar J, Hood SD.  Tryptophan Depletion Study in Irritable Bowel Syndrome (IBS). The Royal College of Psychiatrists Section of Liaison Psychiatry Residential Conference. Barcelona, Spain.  March 19-21, 2003
REF 143.   Argyropoulos SV, Adrover M, Hood SD, Bell C, Rich A, Nash J, Rich N, Nutt DJ. Tryptophan depletion in treated social anxiety disorder: effects of autobiographical scripts and stressful speaking tasks. British Association for Psychopharmacology Summer Meeting. Harrogate, UK. July 2002.
REF 144.   Sargent P, Nash J, Hood SD, Rabiner E, Messa C, Cowen P, Nutt DJ, Grasby P. 5-HT1A Receptor Binding in Panic Disorder; comparison with Depressive Disorder and Healthy Volunteers using PET and [11C] WAY-100635.  Sixth Annual Meeting of the Organization For Human Brain Mapping.  June 12-16, 2000.